TG Therapeutics Inc., of New York, recapped data from two triple-combo therapy trials using TGR-1202 (umbralisib), its oral, next-generation PI3K delta inhibitor, and TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, as the backbone of the combinations at the European Hematology Association meeting in Madrid, Spain.